| gap-pubmed-20260410- | How can mechanistic understanding of NGsAb pathogenesis inform more refined ther | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What upstream triggers initiate NGsAb production against specific neuroglial sur | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines which effector mechanisms NGsAbs utilize in different patients o | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does CAV1-mediated CLDN5 redistribution mechanistically occur during hypoxia | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | What molecular mechanisms control the selective autophagy targeting of CAV1 vers | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | How does RIPK1 activity differ across CNS cell types and which cells are most th | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which RIPK1 inhibition prevents ne | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does metabolic dysfunction in neurodegenerative diseases drive pathological tau | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TDP-43 cytoplasmic redistribution mechanistically alter tau isoform rat | resolved | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanism drives insulin-induced 4R-tau expression in development | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the causal relationship between immune cell proportion changes and epige | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do occupational exposures mechanistically drive epigenetic age acceleration | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain why epigenetic age acceleration affects ALS survival pre | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does LPS-induced glycolytic shift divert energy from glutamate uptake withou | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms link astrocyte S100B signaling to glycolytic enzyme ac | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the relative contributions of calpain vs proteasome pathways to | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does calpain selectively target specific MAPs while sparing others in HSN1A | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanism links SPTLC1 mutations to mitochondrial calcium depleti | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does Parkin regulate mitochondrial biogenesis alongside its established role | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms underlying the functional alliance be | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can understanding methamphetamine toxicity mechanisms inform treatment strat | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-pubmed-20260410- | What determines tissue-specific activation of different methamphetamine toxicity | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-pubmed-20260410- | How do genetic polymorphisms in drug metabolism modulate methamphetamine neuroto | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-pubmed-20260410- | What determines the differential efficiency between full-length and shortened AR | open | 0.77 | 0.00 | 2026-04-10 | 0 | | gene-therapy |
| gap-pubmed-20260410- | How do ARMMs achieve neuronal cell targeting specificity compared to other extra | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable ARRDC1-mediated packaging of large CRISPR-Cas9 | open | 0.80 | 0.00 | 2026-04-10 | 0 | | gene-therapy |
| gap-pubmed-20260410- | How do astrocytic calcium responses specifically contribute to memory persistenc | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | cognitive-neuroscience |
| gap-pubmed-20260410- | What molecular mechanisms link α7-nicotinic receptor activation to astrocytic ca | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What tissue-specific mechanisms explain how FEZ2 expression in excitatory neuron | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do cytoskeleton and autophagy pathway dysregulations causally link sarcopeni | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the localized genetic correlations between sa | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does YQTL activate multiple seemingly redundant neuroprotective pathways sim | open | 0.73 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | How do the 15 brain-absorbed YQTL compounds selectively target the 82 identified | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | Which specific adipokines and immune cell populations in adipose tissue are the | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which adipose tissue-derived infla | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines why only some individuals with RHI exposure develop CTE patholog | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why can CTE only be diagnosed postmortem when other tauopathies have emerging bi | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive the unique perivascular p-tau accumulation patte | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does PICALM specifically regulate the endosomal trafficking of APP to amyloi | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link PICALM SNPs to altered APP endocytosis and Aβ gen | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do current therapeutic approaches beyond exercise show limited efficacy in I | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the mechanistic pathways linking newly identified multiomic biomarkers | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does BL-OG compare to established activity-dependent regeneration therapies | open | 0.74 | 0.00 | 2026-04-10 | 0 | | nerve-regeneration |
| gap-pubmed-20260410- | Why does single-dose CTZ treatment produce sustained regenerative effects over 4 | open | 0.77 | 0.00 | 2026-04-10 | 0 | | nerve-regeneration |
| gap-pubmed-20260410- | What molecular mechanisms mediate bioluminescent optogenetics enhancement of axo | open | 0.80 | 0.00 | 2026-04-10 | 0 | | nerve-regeneration |
| gap-pubmed-20260410- | How does CXCR4 blockade specifically modulate immunosuppressive cell infiltratio | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms drive self-accelerating STING agonist release from the nanoplatf | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do different clusterin isoforms (secreted vs nuclear) contribute to neurodeg | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether clusterin functions as a multifunctional protein versus | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does clusterin exacerbate or protect against neuronal death in neurodegeneration | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |